Opinion|Videos|October 9, 2025
Video: Exploring the Role of IL-13 Inhibition in AD: Clinical Perspectives & Practical Applications
A pair of leading subject matter experts discuss the current landscape of atopic dermatitis, including unmet needs, and the role of IL-13 inhibition in the management.
Advertisement
Advertisement
Related to this article
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.
All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Advertisement
Advertisement
Trending on HCPLive
1
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
2
EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis
3
8 Endocrinology Headlines You Missed in Q3 2026
4
Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis
5